

Supplemental Table 1 Propensity Score Matching Characteristics in Commercial and Medicare Supplemental MarketScan® Multiple Myeloma Unmatched Control Patients Without Renal Impairment

Variable	Unmatched Control Cohort (n=7278)
Demographic characteristics	
Age group in years, n (%)	
18–34	86 (1.2%)
35–44	373 (5.1%)
45–54	1406 (19.3%)
55–64	2685 (36.9%)
65–74	1449 (19.9%)
75+	1279 (17.6%)
Sex, n (%)	
Male	3481 (47.8%)
Female	3797 (52.2%)
Payer, n (%)	
Commercial	4458 (61.3%)
Medicare Supplemental	2820 (38.7%)
Health plan type, ^a n (%)	
Comprehensive (traditional/indemnity)	1237 (17.0%)
EPO/PPO	3961 (54.4%)
HMO	452 (6.2%)
POS with or without capitation	973 (13.4%)
Other/unknown	655 (9.0%)
Geographic region, n (%)	
Northeast	1470 (20.2%)
North central	1907 (26.2%)
South	2548 (35.0%)
West	1276 (17.5%)
Unknown	77 (1.1%)
Urban/Rural residence, n (%)	
Urban	6190 (85.1%)

Variable	Unmatched Control Cohort (n=7278)
Rural	1013 (13.9%)
Unknown	75 (1.0%)
Index year, n (%)	
2008	1836 (25.2%)
2009	939 (12.9%)
2010	848 (11.7%)
2011	952 (13.1%)
2012	1002 (13.8%)
2013	763 (10.5%)
2014	692 (9.5%)
2015 ^b	246 (3.4%)
Clinical characteristics	
Highest CKD stage on the index date, n (%)	
Stage I	N/A
Stage II	N/A
Stage III	N/A
Stage IV	N/A
Stage V	N/A
Deyo-Charlson Comorbidity Index, n (%)	
0	941 (12.9%)
1-2	4472 (61.4%)
3-4	1645 (22.6%)
5+	220 (3.0%)
Comorbid conditions ^c , n (%)	
Amyloidosis	117 (1.6%)
Anemia or anemia treatment	583 (8.0%)
Coronary heart disease	650 (8.9%)
Gastrointestinal bleeding	215 (3.0%)
Hypercalcemia	141 (1.9%)
Hypertension	2393 (32.9%)

Variable	Unmatched Control Cohort (n=7278)
Major bleeding	522 (7.2%)
Neutropenia	292 (4.0%)
Overweight/obesity	243 (3.3%)
Peripheral neuropathy	542 (7.4%)
Peripheral vascular disease	84 (1.2%)
Pneumonia	387 (5.3%)
Skeletal related event	800 (11.0%)
Thrombocytopenia	304 (4.2%)
Venous thrombembolism	265 (3.6%)
Pain diagnosis	283 (3.9%)
Medication use ^c , n (%)	
Opioid analgesic medication	3121 (42.9%)
Nephrotoxic medication	1432 (19.7%)
Anti-myeloma therapy	1865 (25.6%)
Bone-targeting agents	1029 (14.1%)
NSAID	1128 (15.5%)
Other variables	
Mean (SD) log of total baseline healthcare costs, PPPY	4.79 (5.01)
Mean (SD) number of days between multiple myeloma diagnosis and index date	164 (253)

EPO=Exclusive provider organization; HMO=health maintenance organization; POS=point-of-service plan; PPO=preferred provider organization; PPPY=per-patient per-year; RI=renal impairment.

Percentages may not add up to 100% because of rounding.

^aOther insurance plan types included consumer-driven health plans and high-deductible health plans. Unknown plan type included patients who were missing an insurance plan type.

^bData used in this analysis only included up through September 30, 2015.

^cPatients could have more than one comorbidity and more than one medication used.